Anti-C3d Antibody [053A-514.3.1.4] (A278906)

Anti-C3d Antibody [053A-514.3.1.4]

Mouse monoclonal [053A-514.3.1.4] antibody to C3d.

This antibody recognises human complement component 3d (C3d) neoantigen, a ~33 kDa polypeptide fragment generated over the course of complement activation in which where complement 3 (C3) convertases cleave C3 to C3b, which is further degraded into iC3b and C3dg/C3d. C3d is involved in the regulation of many aspects of the immune response, including antigen processing and presentation. The C3d/antigen complex mediates B cell activation by simultaneously binding antigen-specific surface bound immunoglobulin and CD21, lowering the complement activation threshold. C3 is crucial in the induction of tolerance generated when an antigen is introduced into immunoprivileged sites and this is exploited by pathogens and cancer cells to evade the immune system by inhibiting complement activation.

Flow Cytometry, ELISA, IHC-Fr

Human

Purified human C3d (neoantigen).

Mouse

Monoclonal

053A-514.3.1.4

IgG1

Lot Specific

Liquid

Supplied in Borate Buffered Saline with 0.1% Sodium Azide.

Shipped at ambient temperature. Upon delivery aliquot and store at -20°C. When thawed, aliquot the sample as needed. Short term (up to 4 weeks): store at 4°C. Long term: store at -20°C. Avoid freeze / thaw cycles. Storage in frost free freezers is not recommended.

Mouse anti Human C3d antibody, clone 053A-514.3.1.4 recognizes human complement component 3d (C3d) neoantigen, a ~33 kDa polypeptide fragment generated over the course of complement activation in which where complement 3 (C3) convertases cleave C3 to C3b, which is further degraded into iC3b and C3dg/C3d. C3d is involved in the regulation of many aspects of the immune response, including antigen processing and presentation. The C3d/antigen complex mediates B cell activation by simultaneously binding antigen-specific surface bound immunoglobulin and CD21, lowering the complement activation threshold. C3 is crucial in the induction of tolerance generated when an antigen is introduced into immunoprivileged sites and this is exploited by pathogens and cancer cells to evade the immune system by inhibiting complement activation.